PROGRESSING PRC 210 TO CLINICAL TREATMENT FOR THE PREVENTION OF NEURODEGENERATIVE DISEASES AFTER RADIATION

$1,081,762FY2025Defense Health AgencyDOD

Obvia Pharmaceuticals, Ltd.

Investigators